A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m(2), rituximab 375 mg/m(2) (pola + BR) Q3W for up to six cycles in patien...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Terui, Yasuhito, Rai, Shinya, Izutsu, Koji, Yamaguchi, Motoko, Takizawa, Jun, Kuroda, Junya, Ishikawa, Takayuki, Kato, Koji, Suehiro, Youko, Fukuhara, Noriko, Ohmine, Ken, Goto, Hideki, Yamamoto, Kazuhito, Kanemura, Nobuhiro, Ueda, Yasunori, Ishizawa, Kenichi, Kumagai, Kyoya, Kawasaki, Atsuko, Saito, Tomohisa, Hashizume, Misato, Shibayama, Hirohiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8253277/
https://ncbi.nlm.nih.gov/pubmed/33942442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14937
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak